Impact of Combined Cannabis and Tobacco Use on Brain Chemistry

Joint Use of Cannabis and Tobacco and Its Effects on the Brain

A recent study from McGill University indicates that individuals who use both cannabis and tobacco exhibit distinct chemical patterns in the brain, leading to increased levels of anxiety, depression, and difficulty in quitting cannabis. Brain scans reveal elevated levels of the enzyme FAAH, which breaks down the happiness molecule known as anandamide.

The study showed that people who use both cannabis and tobacco have higher levels of FAAH enzyme compared to those who use only cannabis. This enzyme is responsible for breaking down anandamide, a molecule known for its role in mood regulation and stress relief.

This chemical change results in reduced natural anandamide in the brain, increasing individuals’ susceptibility to anxiety, depression, and difficulty in quitting cannabis. The findings reveal a potential biological target for treating cannabis use disorder, especially among those who also use tobacco.

Psychological and Social Effects of Joint Use

The chemical imbalances resulting from the combined use of cannabis and tobacco may explain why joint users face greater mental health challenges and more difficulty quitting cannabis compared to those who use cannabis alone. Studies suggest that lower levels of anandamide are associated with poor psychological outcomes such as increased anxiety and depressive tendencies.

Additionally, joint use contributes to heightened risks of depression and relapse when attempting to quit cannabis. This suggests that the combined use of cannabis and tobacco is not merely a matter of bad habits but has actual biological effects on the brain.

Potential for Developing Targeted Treatments

The study highlights the importance of understanding the biological mechanisms behind the harmful effects of combined cannabis and tobacco use. Identifying these mechanisms could aid in developing targeted medications to treat cannabis use disorder, particularly among tobacco users.

Currently, available treatments for this disorder are limited to behavioral therapies such as counseling. However, with advances in understanding how joint use affects brain chemistry, we may soon see the development of effective drugs targeting these mechanisms.

Conclusion

The recent study from McGill University provides new insights into the harmful effects of combined cannabis and tobacco use on the brain. By understanding how the FAAH enzyme affects anandamide levels, we can begin to develop new treatments aimed at improving the mental health of individuals suffering from cannabis use disorder. Raising awareness of these effects can help spur further research in this field and the development of innovative therapeutic solutions.